Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.

ABSTRACT: The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum mi

SUBMITTER: Satomi-Tsushita N 

PROVIDER: S-EPMC6726239 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature